Mural Oncology plc is a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural Oncology plc is based in DUBLIN, Ireland.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-128.51M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -107.76% |
| Return on Assets (Trailing 12 Months) | -87.57% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.87 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.39 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.77 |
| Earnings per Share (Most Recent Fiscal Year) | $-7.58 |
| Diluted Earnings per Share (Trailing 12 Months) | $-8.59 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 17.32M |
| Free Float | 16.94M |
| Market Capitalization | $35.86M |
| Average Volume (Last 20 Days) | 0.61M |
| Beta (Past 60 Months) | 3.00 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 80.21% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |